The grades of six Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
NPS Pharmaceuticals‘ (NASDAQ:NPSP) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). NPS Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. In Portfolio Grader’s specific subcategory of Sales Growth, NPSP also gets an A. For more information, get Portfolio Grader’s complete analysis of NPSP stock.
Grifols (NASDAQ:GRFS) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Grifols S. A. develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. Shares of GRFS have increased 14.1% over the past month, better than the 2.6% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of GRFS stock.
Amicus Therapeutics (NASDAQ:FOLD) improves from a C to a B rating this week. Amicus Therapeutics is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. Wall Street has pushed the stock higher by 2% over the past month. For more information, get Portfolio Grader’s complete analysis of FOLD stock.
Maxygen‘s (NASDAQ:MAXY) ratings are looking better this week, moving up to a B from last week’s C. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock has a trailing PE Ratio of 3.40. For more information, get Portfolio Grader’s complete analysis of MAXY stock.
Allos Therapeutics (NASDAQ:ALTH) gets a higher grade this week, advancing from a C last week to a B. Allos is a biopharmaceutical company focused on developing and commercializing small-molecule drugs that treat cancer. For more information, get Portfolio Grader’s complete analysis of ALTH stock.
This week, Insmed Inc.‘s (NASDAQ:INSM) ratings are up from a C last week to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 83% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.